{"id":"NCT04186403","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)","officialTitle":"A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-01-13","primaryCompletion":"2021-09-22","completion":"2021-09-22","firstPosted":"2019-12-04","resultsPosted":"2024-10-03","lastUpdate":"2024-10-03"},"enrollment":201,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Borderline Personality Disorder"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":["Rexulti","OPC-34712"]}],"arms":[{"label":"Prior Brexpiprazole 2-3 Milligrams Per Day","type":"EXPERIMENTAL"},{"label":"Prior Placebo","type":"EXPERIMENTAL"}],"summary":"This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and as Per Severity","timeFrame":"Signing of ICF up to 30 days post last dose of study drug (up to approximately 16 weeks)","effectByArm":[{"arm":"Prior Brexpiprazole 2-3 mg/Day","deltaMin":30,"sd":null},{"arm":"Prior Placebo","deltaMin":56,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["39558901"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":88},"commonTop":["Insomnia","Akathisia","Fatigue","Restlessness","Weight increased"]}}